Value Proposition

Oncology market

Pricing

  • Since 1995, there has been a marked increase in the price of new cancer drugs corresponding to the uptake of biologics in oncology. Most agents launched between 2009 and 2014 cost more than $100,000 USD per year. More recently developed agents, such as CAR T-cell therapy, may cost up to almost $500,000 USD per year. (American Society of Clinical Oncology Educational Book, vol 41).
  • Recently, the industry saw four major cancer biotech acquisitions: Agilent Technologies’ takeover of precision oncology liquid biopsy developer Resolution Biosciences; Takeda’s buy-out of Maverick Therapeutics and its T cell immuno-oncology technology; Amgen’s purchase of Five Prime’s immuno-oncology assets; and Hologic Inc.’s acquisition of molecular oncology leader Biotheranostics Inc.
  • The mega biotech acquisition deals, ranging between a quarter to over half a billion dollars, reflects the expanding oncology market (xtalks, 21st March 2021).
  • The pricing of cancer drugs involves several factors and the price of PENAO will be informed by study results and the contemporary market.